ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The selective tyrosine kinase inhibitors (TKI), which target the ATP binding site of BCR/ABL, block BCR/ABL kinase activity and exhibit a positive therapeutic effect for CML (10,11).